Socioeconomic and humanistic burden of illness of EDS associated with OSA in the Eu5: analysis of national health and wellness survey data

Jennum, Poul; Coaquira, J.; Mettam, Sam; Khakevitch, T.; Bron, Morgan; Cambron-Mellott, M. Janelle

doi:10.1016/j.sleep.2019.11.481

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7][8][9] Furthermore, a recent study demonstrated a relationship between severity of EDS (as measured by the Epworth Sleepiness Scale) and degree of impairment in QoL and functioning such that increasing severity of EDS is associated with a greater degree of impairment. 10 Solriamfetol (Sunosi; Jazz Pharmaceuticals, Palo Alto, CA) is a dopamine and norepinephrine reuptake inhibitor approved in the United States and the European Union to improve wakefulness in adults with EDS associated with narcolepsy (75 to 150 mg/day) or OSA (37.5 to 150 mg/day). 11,12 Solriamfetol has been shown to have short-term and long-term efficacy in the treatment of EDS in patients with narcolepsy or OSA.…”

Section: Introductionmentioning

confidence: 99%

Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea

Weaver

Pépin

Schwab

et al. 2021

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union for excessive daytime sleepiness in adults with narcolepsy (75-150 mg/day) or obstructive sleep apnea (OSA; 37.5-150 mg/day). In 12-week studies, solriamfetol was associated with improvements in quality of life in participants with narcolepsy or OSA. These analyses evaluated the long-term effects of solriamfetol on quality of life. Methods: Participants with narcolepsy or OSA who completed previous solriamfetol studies were eligible. A 2-week titration was followed by a maintenance phase ≤ 50weeks (stable doses: 75, 150,or 300mg/day). Quality oflife assessments included Functional Outcomes of Sleep Questionnaireshort version, WorkProductivity and Activity Impairment Questionnaire: Specific Health Problem, and 36-Item Short Form Health Survey version 2. Mean (standard deviation) changes from baseline to end of study were evaluated. Data were summarized descriptively. Adverse events were assessed. Results: Safety population comprised 643 participants (417 OSA, 226 narcolepsy). Solriamfetol improved Functional Outcomes of Sleep Questionnaire short version Total scores (mean change [standard deviation], 3.7 [3.0]) and 36-Item Short Form Health Survey version 2 Physical and Mental Component Summary scores (3.1 [6.9] and4.3 [8.4], respectively); improvements were sustained throughout treatment. On WorkProductivity and Activity Impairment Questionnaire: Specific Health Problem, solriamfetol reduced (improved) % presenteeism, % overall work impairment, and % activity impairment by a minimum of 25%. Common adverse events (≥ 5%): headache, nausea, nasopharyngitis, insomnia, dry mouth, anxiety, decreased appetite, and upper respiratory tract infection. Conclusions: Long-term solriamfetol treatment was associated with clinically meaningful, sustained improvements in functional status, work productivity, and quality of life for up to 52 weeks. Adverse events were similar between narcolepsy and OSA.

show abstract